AI in Healthcare

Today's Stories

1. 1

   Merck's intismeran win lifts shares, backs $1.5B Tempus AI sale

   Merck (MRK) shares rose after positive trial results for its personalized cancer vaccine intismeran autogene, developed with Moderna, revived investor interest. Merck holds a 13% stake in Personalis and will vote for Tempus AI's $1.5B acquisition at $16.25 per share. The stake in Personalis and support for Tempus AI tie strategic sequencing partnerships to Merck's cancer vaccine program, signaling a deeper integration of data and diagnostics into its oncology pipeline. This could strengthen its position in personalized medicine.

   The trial results and the Tempus AI vote are likely to be key catalysts for Merck's stock. Watch whether the $1.5B acquisition at $16.25 per share closes, as it may affect Merck's sequencing partnerships.

2. 2

   Sands Capital sees AI-driven upside in Intuitive Surgical

   Sands Capital Global Growth Fund highlighted Intuitive Surgical (ISRG) in its Q2 2026 investor letter, saying it expects the company to roll out AI features over the next few years. These include anatomy identification, critical structure highlighting during surgery, and, over time, support for surgeon dexterity and automation. The fund believes the share price pressure on Intuitive obscures a stronger fundamental setup, noting Q1 2026 results beat consensus estimates across revenue, non-GAAP earnings, non-GAAP operating margins, da Vinci procedures, and robot placements. It expects AI features to accelerate robotic surgery adoption and create a software licensing opportunity with higher gross margins.

   Intuitive's shares closed at $366.70 on September 04, 2026, down 21.98% over the past year, trading at levels not seen since 2022, per the fund. The question is whether the AI rollout can drive a rerating, though the fund does not expect a quick one.

3. 3

   AI-designed drug shows signs of reversing biological aging

   Insilico Medicine reports that rentosertib, an AI-designed drug originally developed for idiopathic pulmonary fibrosis (IPF), appears to reverse markers of biological aging. Six independent aging clocks predicted that treated patients were biologically up to six years younger than the placebo group. This is the first study to show clearly that predicted biological age can be reduced, according to Vadim Gladyshev of Harvard Medical School. However, the trial involved only 42 patients, and the results may only apply to those with the lung disease, not healthy people.

   The study falls short of a definitive trial, so the key test is whether larger studies in healthy people confirm the effect. Rentosertib is currently in a Phase III trial for IPF, the final stage before potential approval.

4. 4

   FDA clears first autonomous blood-draw robot Aletta

   The U.S. Food and Drug Administration gave the go-ahead on 19 August for Aletta, the first autonomous blood-draw device authorized for use in the United States, developed by Dutch medical robotics firm Vitestro. In a clinical trial involving more than 1,600 people in the Netherlands, Aletta successfully drew blood on the first attempt in 94.5 percent of cases, even among those with hard-to-access veins, people with obesity, and the elderly. The device could address staffing shortages in a profession with a median annual turnover rate of nearly 25 percent and a vacancy rate of close to 10 percent.

   The main caveat is whether Aletta performs well for people with darker skin tones, as melanin can interfere with the near-infrared light used to map veins. Vitestro says its ultrasound sensor, which is "skin-tone agnostic," mitigates this risk, but experts want more evidence.

5. 5

   AI helps train dogs to sniff cancer in India

   Researchers in Bengaluru, India, are using AI to train rescue dogs like Chloe to sniff human breath for cancer, aiming to develop a noninvasive test. The dogs wear a 3D-printed helmet and harness packed with sensors. A growing body of global research suggests dogs can be trained to detect cancer and other illnesses, from Parkinson's to COVID-19. This project could lead to a new, noninvasive way to screen for the disease.

   The success of the effort hinges on whether the AI can effectively interpret the sensor data from the dogs' sniffs to reliably identify cancer. The test's accuracy will determine if it becomes a viable diagnostic tool.

6. 6

   Pfizer shifts from market-share wins to AI-driven growth story

   Pfizer's earnings calls now emphasize an AI-native R&D organization and a risk-adjusted high single-digit revenue CAGR from year-end 2028, rather than past product-level market share achievements. This pivot comes as core revenue declined 2% over the past year and net margins fell to 6.8% from a three-year peak of 16.8%, raising questions about near-term growth.

   The key test is whether the launched and acquired product portfolio, which delivered $3.2 billion this quarter, can accelerate enough to fill the gap left by slowing blockbuster sales.